The array comparative genomic hybridisation (aCGH) RGCC test is used to identify chromosomal abnormalities in a patient that could lead to cancer. During the test, scientists use a technique called array comparative genomic hybridisation to spot abnormalities in a genome. This insight enables them to assess the likely risk of cancer developing and the potential […]
Metastat RGCC is an advanced test to detect specific blood-borne markers that can accurately determine whether a secondary cancerous tumour is likely to develop and its potential location. During the test, we analyse a sample of a patient’s blood in our state-of-the-art laboratory to analyse, identify and measure circulating tumour cells (CTCs). Metastat RGCC is […]
Oncotrail RGCC provides crucial information on the presence of circulating tumour cells (CTCs) and their concentration in patients who have a confirmed diagnosis of specific forms of cancer, including breast, colon and prostate cancer. During the test, a sample of blood is analysed to identify the presence and concentration of CTC and their immunophenotype. Oncotrail […]
Oncotrace RGCC is used to identify a primary tumour in a patient and to provide guidance about disease progression and future prognosis. During the test, a sample of blood is analysed to identify the presence and concentration of circulating tumour cells (CTCs) and their concentration. This test provides information about the presence of CTCs, their […]
Oncocount RGCC detects the presence of circulating tumour cells (CTCs) and their concentration in the blood. CTCs are a powerful biomarker, and their presence in the blood can act as an early warning sign that cancer is returning. The test is designed as a follow-up test for patients who have cancer and are worried about […]
Can brain tumours also be tested with a blood sample?
No, due to the blood-brain barrier, tumour cells cannot enter the bloodstream. This means that we cannot obtain and isolate any tumour cells from the blood sample.
Is it possible to measure circulating tumour cells (CTC) in patients with lymphoma or leukaemia?
Yes, patients with lymphoma or leukaemia can use an RGCC test to measure the number of circulating tumour cells (CTC) they have.
Which test is the most comprehensive test?
The most comprehensive test is the “Onconomics Plus” test. This provides information on the sensitivity or resistance of the patient’s tumour cells to certain cancer drugs and shows options for targeted therapy or an alternative treatment method with organic substances. The test also contains information about the development of the tumour and its potential by identifying epigenetic tumour markers relevant for the therapy, which are crucial for the correct therapeutic approach.
How do online consultations work?
Online consultations will give you the opportunity to speak to any member of the RGCC Network at a time and place that is convenient to you. You will be able to choose from a shortlist of clinicians who best suit your needs. The online consultation will be available via the Cancer A-Z app soon… please keep checking the app for updates.
Will online consultations take place via Zoom, Skype or another method?
Your chosen clinician will be in touch to make the arrangements and choose the most convenient method.
Didn't find an answer to your question? Contact us directly.